CollPlant Biotechnologies Ltd Dossier - Source-backed chat

CollPlant Biotechnologies Ltd

CLGNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.79

Intrinsic Value $3.50median of 2 methodsbased on filings through 31 Dec 2025

Market Price $3.57Price as of 1 Oct 2026

Near fair valueIntrinsic value is 2% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $6.8M

Enterprise Value $1.2M

Shares Outstanding 1.9M diluted

Next Earnings Date25 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CollPlant Biotechnologies is a pioneer in regenerative and aesthetic medicine, utilizing its proprietary plant-based recombinant human collagen (rhCollagen) platform. While the company possesses highly innovative technology, including 3D bioprinting applications and photocurable dermal fillers, it faces significant near-term headwinds. The termination of its development agreement with AbbVie has severely impacted its revenue outlook, leading to a companywide cost-reduction plan and a ~50% workforce reduction. With a limited cash runway of $4.3 million as of March 31, 2026, and a pending Nasdaq minimum bid price deficiency, the company has initiated a review of strategic alternatives. Investors should remain on the sidelines until there is greater clarity on strategic transactions or new commercial partnerships.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1015%

The bear case materializes if CollPlant fails to secure a strategic partner or buyer, and its cash reserves continue to deplete rapidly. Continued high cash burn from preclinical programs without offsetting milestone revenues would force highly dilutive equity offerings. Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting, severely reducing stock liquidity and investor interest.

Base CaseCentral scenario

$0.5060%

The base case assumes CollPlant continues to operate as a standalone entity while actively seeking strategic alternatives. Revenue remains minimal in the near term following the AbbVie termination, and the company relies on its reduced cost structure (~50% headcount reduction) to extend its cash runway. The company may need to execute a reverse stock split to maintain its Nasdaq listing before the September 21, 2026 deadline. Valuation is constrained by execution risks and the need for dilutive capital raises or a business combination.

Bull CaseUpside scenario

$1.5025%

The bull case is driven by successful commercialization of the photocurable dermal filler platform and the ready-to-print BioFlex bioprinting portfolio. If CollPlant secures a major global pharmaceutical or aesthetics partner to replace AbbVie, it could trigger substantial milestone payments and validate its technology. Additionally, rapid adoption of its rhCollagen by research institutions (like the Mayo Clinic's 3D bioprinted skin model) as an alternative to animal testing could open up a high-margin, high-growth revenue stream.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary plant-based rhCollagen platform offering a highly pure, consistent, and non-animal-derived alternative to traditional animal-derived collagen.
Strong intellectual property portfolio with recently granted patents in the US, South Korea, and Japan covering photocurable dermal filler and curable bioink technologies.
Diverse pipeline addressing high-growth markets, including medical aesthetics (dermal fillers, regenerative breast implants) and 3D bioprinting of tissues and organs.

Key Investment Risks

Severe revenue decline and loss of validation following the termination of the AbbVie development and commercialization agreement.
Limited cash runway ($4.3 million as of March 31, 2026) necessitating further capital raises, strategic transactions, or business combinations.
Nasdaq listing deficiency due to the bid price remaining below $1.00, with a compliance deadline of September 21, 2026.

Thesis Invalidation Triggers

Announcement of a major new development and commercialization partnership with a leading global aesthetics or pharmaceutical company.
Successful acquisition or business combination resulting from the ongoing strategic alternatives review.
Delisting from the Nasdaq Capital Market if the company fails to regain compliance with the minimum bid price requirement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.